Scott Kathleen D. 4
4 · ARS Pharmaceuticals, Inc. · Filed Oct 17, 2024
Insider Transaction Report
Form 4
Scott Kathleen D.
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-10-16$1.50/sh+12,500$18,750→ 17,449 total - Sale
Common Stock
2024-10-16$16.00/sh−12,500$200,000→ 4,949 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-16−12,500→ 802,330 totalExercise: $1.50Exp: 2032-02-29→ Common Stock (12,500 underlying)
Holdings
- 8,250(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]The Reporting Person inadvertently added the holdings of Scott 2008 Trust Dated 3/28/08 (the "Trust") as directly held on her Form 4 filed on August 20, 2024. As of the date of that Form 4, the Reporting Person owned 8,250 shares indirectly through the Trust.
- [F2]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024.
- [F3]By the Trust.
- [F4]Immediately exercisable.